Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1744)	5/25/2001 9:10:59 AM
From: Ian@SI	Read Replies (1) \| Respond to of 2344

Bernard, Thanks for the effort. I had thought that I was just being exceptionally dense; rather than Alex's answer being somewhat ambiguous. Re Pat testimonial: I was under the impression that the lung metastasis after breast cancer is resistant to all available cancer treatments. i.e. - getting the recurrence was a near certain death sentence. IMO, for Pat to scan cancer free, is absolutely extraordinary even considering the high hopes we hold for Theratope. While it's premature to make conclusions, it certainly appears that BIOM will provide hope for women who previously had none; and that Theratope can be quite effective in stimulating the body's immune response when treatment starts early enough. RAGL, Ian.